Journals / Fırat Tıp Dergisi / 2021 / Cilt: 26 - Sayı: 4

Investigation of Atypical Pathogenes Using Indirect Immunfluorescan Antibody Method (IFA) in Community-Developed Pneumonies

Çocukluk Çağında Toplumdan Gelişen Pnömonilerde Atipik Patojenlerin İndirekt İmmünfloresan Antikor Yöntemi (İFA) ile Araştırılması

Pages
211–217
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In statistical analyse, seropositivity of patients’ group was significantly higher than control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to investigate seropositivity of specific IgM antibodies developed against atypical pneumoniae pathogens and to compare this with the control group.
📊
Key Findings & Data:Material and Method: Serum samples taken from 90 pediatric patients who were diagnosed with CAP in the 0-14 age group and whose condition was serious enough to require hospitalization and 30 healthy children, a single IFA kit was used for the most common 20 atypical pathogens (Respiratory Tract Profile IgM, Euroimmune, Lübeck, Germany).
💡
Conclusion & Impact:In statistical analyse, seropositivity of patients’ group was significantly higher than control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to investigate seropositivity of specific IgM antibodies developed against atypical pneumoniae pathogens and to compare this with the control group. Material and Method: Serum samples taken from 90 pediatric patients who were diagnosed with CAP in the 0-14 age group and whose condition was serious enough to require hospitalization and 30 healthy children, a single IFA kit was used for the most common 20 atypical pathogens (Respiratory Tract Profile IgM, Euroimmune, Lübeck, Germany). The frequency of these factors, the distribution of factors according to age, gender and seasons were determined. This study does not cover pneumonia that develops in patients with congenital or acquired immunodeficiency and patients with underlying chronic diseases. Results: There were seropositivity at 61 children in patients’ group and 7 children in control group. Sensitivity and specifity of the test were 76,7%. In statistical analyse, seropositivity of patients’ group was significantly higher than control group (p

Özet

Amaç: Bu çalışmada toplumdan gelişen pnömoni (TGP) tanısı almış çocuk hastalarda, atipik pnömoni etkenlerine karşı özgül IgM antikorlarının seropozitifliğinin İFA yöntemiyle araştırılması ve kontrol grubuyla karşılaştırması amaçlandı. Gereç ve Yöntem: Çalışmaya 0-14 yaş grubundan TGP tanısı alan, durumu hastaneye yatırmayı gerektirecek kadar ciddi olan 90 çocuk hasta ile 30 sağlıklı çocuktan alınan serum örnekleri, en çok görülen 20 atipik patojen açısından tek bir İFA kiti (Respiratory Tract Profile IgM, Euroimmun, Lübeck, Germany) ile tarandı. Bu etkenlerin sıklığı, etkenlerin yaşa, cinsiyete ve mevsimlere göre dağılımı tespit edilmiştir. Bu çalışma, doğumsal ya da k azanılmış bağışıklık yetmezliği olan hastalar ile altta yatan kronik hastalığı olan hastalarda gelişen pnömonileri kapsamamaktadır. Bulgular: Hasta grubunda 61, kontrol grubunda 7 çocukta seropozitiflik görüldü. Testin duyarlılık ve özgüllüğü %76,7 olarak saptandı. Yapılan istatiksel analizde hasta grubunun seropozitiflik oranı, kontrol grubuna göre anlamlı olarak yüksek bulundu (p

🔖

Cite This Article

SEYREK, A., ÖNCÜ, R., UÇUCU, S. (2022). Investigation of Atypical Pathogenes Using Indirect Immunfluorescan Antibody Method (IFA) in Community-Developed Pneumonies. Fırat Tıp Dergisi, Cilt: 26 - Sayı: 4, 211–217. https://ajindex.com/articles/513423

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. SciELO Public Health 2004; 82: 895-903
  2. Bryce J, Boschi-Pinto C, Shibuya K, Black RE. Estimates of the causes of death in children. The Lancet 2005; 365: 1147-52
  3. DeAntonio R, Yarzabal P, Cruz JP, Schmidt JE, Kleijnen J. Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review. The Hum Vaccin Immunother 2016; 12: 2422-40
  4. Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: The leading killer of children. The Lancet 2006; 368: 1048-50
  5. Scott JAG, Brooks WA, Peiris JM, Holtzman D, Mulholland K. Pneumonia research to reduce childhood mortality in the developing world. J Clin Invest 2008; 118: 1291-300
  6. Mulholland K. Global burden of acute respiratory infections in children: implications for interventions. Pediatr Pulmonol 2003; 36: 469-74
  7. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? The Lancet 2003; 361: 2226-34
  8. Williams BG, Gouws E, Boschi-Pinto C, Bryce J. Estimates of world-wide distribution of child deaths from acute respiratory infections. The Lancet Infect Dis 2002; 2: 25-32
  9. Mulholland K. Perspectives on the burden of pneumonia in children. The Vaccine 2007; 25: 2394-7
  10. Durmus U, Adak FA, Oncel S. Pneumonia in children /Cocuklarda pnomoni. Türkiye Çocuk Enfeksiyon Hastalıkları Dergisi 2008: 167-75
  11. Alhabbab R. Immunofluorescence (IF) Assay Basic Serological Testing. Springer 2018; 44: 119- 26
  12. Mohan K, Pai S, Rao R, Sripathi H. Leprology Techniques of immunofluorescence and their significance. Indian J Dermatol Venereol Leprol 2008; 74: 415
  13. Ozyılmaz E, Akan OA, Gulhan M, Ahmed K, Nagatake T. Major bacteria of communityacquired respiratory tract infections in Turkey. Jpn J Infect Dis 2005; 58: 50-2
  14. Sevinç C, Uçan E. Yaşamı tehdit eden pnömoniler. Türk Toraks Dergisi 2000; 2: 50-7
  15. Oishi T, Fukuda Y, Wakabayashi S et al. Low prevalence of Chlamydia pneumoniae infections during the Mycoplasma pneumoniae epidemic season: Results of nationwide surveillance in Japan. J Infect Chemother 2020; 26: 1116-21
  16. Ben-Yaakov M, Lazarovich Z, Beer S et al. Prevalence of Chlamydia pneumoniae antibodies in patients with acute respiratory infections in Israel. J Clin Pathol 1994; 47: 232-5
  17. Tuuminen T, Va